Through streamlined and parallelized processes, validated assay kits, and advanced analytical tools, Revvity enables researchers to reduce time to market, reach critical mass earlier, and gain deeper data insights for early target identification and validation. The portfolio also addresses urgent scientific challenges by providing the technologies needed to develop novel therapeutic modalities, including targeted protein degradation as well as cell and gene therapies.

Revvity provides a comprehensive portfolio of high-performance reagents designed to empower researchers and clinicians in achieving significant scientific breakthroughs. Their extensive selection—which includes immunoassays, gene editing and modulation tools, primary and secondary antibodies, and specialized molecular biology solutions—is engineered to transform research productivity and improve clinical outcomes. By offering a diverse range of reagent technologies, Revvity ensures that laboratories can find the precise tools required for their specific needs, whether through their core product categories or their broader, specialized catalog.

From early-stage research to later-stage development, Revvity Signals Software serves scientists working in variety of industries from pharma/Biotech to materials and Specialty Chemical, to clinical sciences.

Revvity recognizes that reliable and early diagnosis serves as the cornerstone of effective disease management. By leveraging cutting-edge technologies and a steadfast commitment to innovation, the organization provides comprehensive solutions designed to support clinicians and biopharma partners. Their offerings are specifically engineered to assist those dedicated to unraveling the complexities of both common and rare diseases, ensuring that critical diagnostic insights are delivered with precision and speed.